ADVENTRX Pharmaceuticals (ANX)
ADVENTRX Pharmaceuticals Cash and ST Investments: 46.05M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ANX Cash and ST Investments Rankings
| Overall | 38th percentile | 2699 of 4393 |
| Sector | 47th percentile | 269 of 509 in Healthcare |
| Industry | 44th percentile | 89 of 159 in Biotechnology |
ANX Cash and ST Investments Range, Past 5 Years
| Minimum | 3.160M | Sep 2009 |
| Maximum | 50.70M | Dec 2011 |
| Average | 27.37M |
About Cash and Short Term Investments
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities
Learn More
You may also be interested in these ANX related companies
ANX News
ADVENTRX Pharmaceuticals to Sponsor & Present at the Martin Center's 2012 Sickle Cell Disease Conference
Apr 16, 8:00AM PR Newswire
Apr 16, 8:00AM PR Newswire
RT @VistaPResearch $ANX Vista Partners Updates Coverage on ADVENTRX Pharmaceuticals; $3.50 Target Price http://stks.co/2zLU
about 64 days ago by StockCowboy
about 64 days ago by StockCowboy
Vista Partners Updates Coverage on ADVENTRX Pharmaceuticals, Inc.; $3.50 Target Price
Mar 21, 9:15AM PR Newswire
Mar 21, 9:15AM PR Newswire
@adamfeuerstein $ANX is ABSOLUTE GARBAGE ! All they do is print paper and pay out banking fees. Culley is a JOKE!!
about 70 days ago by Bullbear123
about 70 days ago by Bullbear123
@StockCowboy $ANX Probably won't have a repeat tomorrow. 150M shelf offering.
about 77 days ago by Random_Walk
about 77 days ago by Random_Walk
RT @GarethSoloway Nice day on $ANX. Market otherwise so quiet. Volume 71.5M. Nuts.
about 77 days ago by InTheMoneyStocks
about 77 days ago by InTheMoneyStocks
ADVENTRX Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference on February 14
Feb 07, 8:00AM PR Newswire
Feb 07, 8:00AM PR Newswire
Biotech Sector on the Upswing -- Dendreon and ADVENTRX Pharmaceuticals Looking Strong
Jan 31, 8:20AM Marketwire
Jan 31, 8:20AM Marketwire
Vista Partners Updates Coverage on ADVENTRX Pharmaceuticals, Inc.; $3.50 Target Price
Dec 15, 9:21AM Benzinga
Dec 15, 9:21AM Benzinga
ADVENTRX (ANX) Discusses ANX-188 Phase 3 Structure w/ FDA; Additional Info Needed for Finalization
Dec 01, 8:40AM Street Insider
Dec 01, 8:40AM Street Insider
Speculative Healthcare Companies IntelGenx and Adventrx Begin to Gain Ground
Nov 15, 8:16AM Marketwire
Nov 15, 8:16AM Marketwire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ANX | 0.5412 | -0.01 | -1.10% | 25.83M |
| ANV | 27.05 | +0.33 | +1.24% | 2.395B |
| ANR | 11.28 | -0.49 | -4.16% | 2.590B |
| ANLY | 3.89 | +0.09 | +2.37% | 19.57M |
| ANEN | 19.00 | -0.14 | -0.73% | 284.99M |
| AMZN | 214.69 | -2.59 | -1.19% | 98.88B |
